End to End CDMO NecstGen offers end-to-end CDMO services for cell therapies and viral vectors, covering preclinical/toxicology material, Phase I/II clinical material, GMP rental, QC, QA, QP services, and technology transfer, enabling clients to advance programs to the clinic within EU regulatory standards.

Localized Manufacturing With a 4,000 m2 development and GMP manufacturing facility in Leiden and flexible hybrid support, NecstGen can act as a regional manufacturing hub, offering scalable production, cleanroom rental, and automation-enabled processes to de-risk supply chains for European biotech partners.

Broad Modality Expertise The organization supports a broad range of modalities including iPSC, CAR-T, TIL, TCR-T, NK and CAR-NK cells, DCs, MSCs, and viral vectors ( LV, AAV ), plus cleanroom rental, creating multiple cross-sell opportunities across diverse client pipelines.

Strategic Partnerships Recent strategic collaborations with Astraveus for CAR-T manufacturing tech evaluation, Galapagos for decentralized manufacturing, and historic partnerships with AUH and Pancancer T, together with active industry events, signal strong growth momentum and credible go-to-market opportunities.

Regulatory and Quality NecstGen emphasizes robust QC, QA, QP support, process and assay development, and regulatory affairs consulting alongside technology transfer, enabling sponsors to meet compliance requirements and accelerate clinical-scale manufacturing with reduced regulatory risk.